Ligand-induced ubiquitination unleashes LAG3 immune checkpoint function by hindering membrane sequestration of

Yong Jiang1, Anran Dai2, Yuwei Huang3

  • 1School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China; Key Laboratory of Multi-Cell Systems, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China.

Cell
|March 18, 2025
PubMed

Insights

Lymphocyte activation gene 3 (LAG3) is activated by non-K48-linked polyubiquitination upon ligand binding, enhancing its immune suppression. This mechanism, targeted by therapeutic antibodies, offers new cancer immunotherapy strategies.

Area of Science:

  • Immunology
  • Molecular Biology
  • Cancer Research

Background:

  • Lymphocyte activation gene 3 (LAG3) is a key immune checkpoint target in cancer immunotherapy.
  • The precise mechanism of LAG3 activation following ligand engagement has remained unclear.

Purpose of the Study:

  • To elucidate the molecular mechanism of LAG3 activation upon ligand binding.
  • To investigate the role of ubiquitination in LAG3 function and its implications for cancer immunotherapy.

Main Methods:

  • Studied LAG3 ubiquitination using biochemical assays and cell-based models.
  • Investigated the role of E3 ligases c-Cbl and Cbl-b in LAG3 ubiquitination.
  • Analyzed the impact of LAG3 ubiquitination on antitumor immunity in vivo.
  • Correlated therapeutic antibody effects with LAG3 ubiquitination levels.

Main Results:

  • Ligand engagement triggers non-K48-linked polyubiquitination of LAG3, enhancing its inhibitory function.
  • Major histocompatibility complex class II (MHC class II) and membrane-bound fibrinogen-like protein 1 (FGL1) induce LAG3 ubiquitination.
  • Ubiquitination, mediated by c-Cbl and Cbl-b, stabilizes the LAG3 cytoplasmic tail, promoting signaling.
  • LAG3 ubiquitination is essential for suppressing antitumor immunity in vivo.
  • Therapeutic LAG3 antibodies inhibit LAG3 ubiquitination, correlating with checkpoint blockade efficacy.

Conclusions:

  • LAG3 activation involves non-K48-linked polyubiquitination, promoting its immune suppressive function.
  • This ubiquitination mechanism is critical for LAG3-mediated T-cell suppression and represents a target for cancer immunotherapy.
  • LAG3/CBL coexpression may serve as a predictive biomarker for response to LAG3 blockade therapies.

Related Concept Videos

Regulated Protein Degradation02:58

Regulated Protein Degradation

It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Hedgehog Signaling Pathway02:33

Hedgehog Signaling Pathway

The Hedgehog gene (Hh) was first discovered due to its control of the growth of disorganized, hair-like bristles phenotype in Drosophila, much like hedgehog spines. Hh plays a crucial role in the development of organs and the maintenance of homeostasis in both invertebrates and vertebrates. However, while Drosophila has only one Hh protein, mammals have multiple functional Hedgehog proteins - Sonic (Shh), Desert (Dhh), and Indian Hedgehog (Ihh). All of these homologous proteins have adapted to...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...